Tandem Diabetes Care, Inc. (TNDM)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tandem Diabetes Care, Inc. (“Tandem” or “the Company”) (NASDAQ: TNDM). Investors who purchased Tandem securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Tandem has violated federal securities laws.
Investigation Details
On August 7, 2025, Tandem disclosed that a malfunction had been identified in some of its insulin pumps, which could “trigger an error resulting in a discontinuation of insulin delivery,” which “could result in hyperglycemia due to discontinuation of insulin delivery” and “may require hospitalization or intervention from a medical professional.” Tandem stated that it had sent notices to impacted customers between July 22 and 24, 2025. Following this news, Tandem’s stock price dropped.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Tandem securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]